SCHEMBL6999859

SCHEMBL6999859

O=c1[nH]c(=O)n2c3c(cccc13)CC2

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
LMNA P02545 2/20 0.50
MEN1 O00255 1/20 0.50
TDP1 Q9NUW8 1/20 0.50
CDK4 P11802 3/20 0.46
CCND1 P24385 3/20 0.46
ALDH1A1 P00352 4/20 0.43
HSD17B10 Q99714 3/20 0.43
USP2 O75604 1/20 0.43
HPGD P15428 1/20 0.43
GSK3A P49840 1/20 0.41
GSK3B P49841 1/20 0.41
KDM4E B2RXH2 9/20 0.41
POLB P06746 3/20 0.41
RAB9A P51151 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
MAPT P10636 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
CYP1A2 P05177 1/20 0.39
MCL1 Q07820 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7005388 0.90 HPGD (0.55) KMT2ALMNAMEN1CDK4CCND1
SCHEMBL7004582 0.89 HPGD (0.50) KMT2ALMNAMEN1CDK4CCND1
SCHEMBL7005451 0.81 HTR3A (0.36) KMT2ALMNAMEN1TDP1CDK4
Hydrochloric Acid SCHEMBL7001168 0.80 HTR2C (0.52) KMT2AMEN1TDP1CDK4CCND1
SCHEMBL7005560 0.78 HTR3A (0.35) KMT2ALMNAMEN1CDK4CCND1
SCHEMBL7003840 0.75 KDM4E (0.38) LMNATDP1ALDH1A1HSD17B10HPGD
SCHEMBL7003839 0.75 KDM4E (0.38) LMNATDP1ALDH1A1HSD17B10HPGD
SCHEMBL7002260 0.74 KDM4E (0.35) LMNACDK4CCND1ALDH1A1HSD17B10
SCHEMBL8137309 0.73 MCL1 (0.50) LMNATDP1POLBMAPTMCL1
Hydrochloric Acid SCHEMBL7001069 0.73 HTR1A (0.71) HTR1ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030105118-A1 Tricyclic quinazolinediones SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-06-05 US disclosed
EP-1288216-A1 TRICYCLIC QUINAZOLINEDIONES SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2003-03-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105118-A1 Tricyclic quinazolinediones PARP1, PARP11, PARP2 KMT2A 1738/4885LMNA 782/4885MEN1 3836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.